

# **LITIGATION RELEVANT TO REGULATION OF NOVEL AND EMERGING NICOTINE AND TOBACCO PRODUCTS**

---

**COMPARISON ACROSS  
JURISDICTIONS**



**World Health  
Organization**



# **LITIGATION RELEVANT TO REGULATION OF NOVEL AND EMERGING NICOTINE AND TOBACCO PRODUCTS**

---

**COMPARISON ACROSS  
JURISDICTIONS**



**World Health  
Organization**

Litigation relevant to regulation of novel and emerging nicotine and tobacco products: comparison across jurisdictions

ISBN 978-92-4-002036-8 (electronic version)

ISBN 978-92-4-002037-5 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Litigation relevant to regulation of novel and emerging nicotine and tobacco products: comparison across jurisdictions. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by Lushomo

# Contents

---

Executive summary . . . . .	iv
Introduction and scope . . . . .	1
Scope and methodology. . . . .	4
<b>1. Product characteristics and disclosures. . . . .</b>	<b>5</b>
Classification hurdles under existing laws . . . . .	5
Prohibition and proportionality . . . . .	8
Flavour bans . . . . .	10
<b>2. Health claims and advertising, promotion, and sponsorship . . .</b>	<b>13</b>
Misleading conduct and false claims . . . . .	13
Restrictions on advertising, promotion and sponsorship. . . . .	14
Conclusion . . . . .	17

# Acknowledgements

---

The report was drafted by Benn McGrady and Kritika Khanijo from the Public Health Law and Policies Unit (LAW), Health Promotion Department. At various stages of preparation, the report benefited from comments, discussions and inputs from the No Tobacco Unit (TFI), WHO: Ranti Fayokun, Sarah Galbraith-Emami, and Vinayak Prasad.

# Executive summary

**N**ovel and emerging tobacco products have presented a number of challenges for regulators, including the risk that regulation may lead to litigation. This paper analyses litigation concerning tobacco product regulation across jurisdictions, with the aim of highlighting the legal arguments advanced and the reasoning of courts relevant to novel and emerging nicotine and tobacco products.

Two broad categories of litigation can be identified. The first concerns measures addressing product

characteristics and disclosures. This group of cases concerns legal challenges against measures which prescribe the form that a product may or may not take, including, classification of these products under national legislation, proportionality of product prohibitions, and flavour bans. The second category of cases concerns health claims and advertising, promotion and sponsorship. These concern application of laws to different products, including enforcement actions concerning misleading conduct and restrictions on advertising, promotion, and sponsorship.

## Key findings

The key findings for the purposes of regulation of novel and emerging nicotine and tobacco products are as follows:

- 1** **manufacturers of e-cigarettes and heated tobacco products attempt to avoid products being regulated, so as to effectively fall within regulatory or legislative gaps;**
- 2** **manufacturers can be expected to deploy arguments concerning the relative risk of different product categories, and the need for coherent regulation along a continuum of risk;**
- 3** **not all courts are receptive to arguments about relative risk, either because regulations are justified by reference to absolute risk or because the concept of relative risk is judged at the population level and taking into account factors beyond relative toxicity;**
- 4** **technological advances employed for the manufacture of novel and emerging nicotine and tobacco products will raise questions of whether a product falls within the ambit and scope of the national legislation of the country;**
- 5** **there are relatively few cases addressing misleading marketing of novel and emerging products, or enforcing restrictions on advertising, promotion and sponsorship, but important cases have been decided, including on how social media posts may constitute advertising and on whether advertising of a heated tobacco product device also constitutes advertising of a tobacco product.**

Together, the cases described offer governments an idea of the legal arguments that have been used in attempts to evade or minimize regulation, as well as how courts have addressed those arguments. For ease of access, those cases are also summarized briefly in the Case Summaries document.<sup>i</sup>

## Two broad categories of tobacco product litigation:

- 1** **PRODUCT CHARACTERISTICS AND DISCLOSURES**
  - Classification hurdles under existing laws
  - Prohibition and proportionality
  - Flavour bans
- 2** **HEALTH CLAIMS AND ADVERTISING, PROMOTION, AND SPONSORSHIP**
  - Misleading conduct and false claims
  - Restrictions on advertising, promotion and sponsorship

<sup>i</sup> World Health Organization, Litigation relevant to regulation of novel and emerging nicotine and tobacco products: case summaries, (2021), (<https://apps.who.int/iris/bitstream/handle/10665/340842/9789240024182-eng.pdf>).

# Introduction and scope

In recent years, regulation of novel and emerging nicotine and tobacco products has taken on increased importance in the context of tobacco control. The emergence of products such as heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS) and their market growth has raised questions about how they should be regulated and how that regulation might affect comprehensive tobacco control. WHO has previously published its position on regulation of these products, but has not addressed legal issues, such as how those regulations are being challenged in different jurisdictions.

HTPs produce aerosols containing nicotine and toxic chemicals when tobacco is heated or when a device containing tobacco is activated.<sup>1</sup> HTPs contain tobacco and are tobacco products and therefore subject to the provisions of the WHO Framework Convention on Tobacco Control (WHO FCTC).<sup>2</sup> Consequently, Parties to the Convention are legally obliged to implement measures including regulating product contents and disclosures (Articles 9 and 10), banning or restricting advertising, promotion and sponsorship (Article 13) and regulating labelling (Article 11).

ENDS are devices that heat a liquid solution to create an aerosol that is inhaled by the user.<sup>3</sup> ENDS is an all-encompassing term for multiple product categories: e-cigarettes, vapes, vape pens, e-cigars, e-hookahs, and e-pipes.<sup>4</sup> There are other electronic, non-nicotine delivery systems (ENNDS), which do not contain nicotine.<sup>5</sup> For the purposes of this report, ENDS, includes ENNDS unless otherwise specified.

In the context of ENDS, where they are not prohibited, WHO has recommended that Member States regulate the products as tobacco products, medicinal products, consumer products, or other categories, as appropriate, taking into account a high level of protection for human health. WHO has recommended that Member States pursue the following general regulatory objectives:

## General regulatory objectives

- a** **impeding ENDS promotion to and uptake by non-smokers, pregnant women and youth;**
- b** **minimizing potential health risks to ENDS users and non-users;**
- c** **prohibiting unproven health claims from being made about ENDS; and**
- d** **protecting existing tobacco-control efforts from commercial and other vested interests of the tobacco industry.<sup>6</sup>**

WHO has also recommended that in order to achieve these objectives, Member States that have not banned the importation, sale, and distribution of ENDS/ENNDS should consider a list of non-exhaustive regulatory options set out in Box 1.<sup>7 8</sup>

1 World Health Organization (WHO), Heated Tobacco Products: Information Sheet, March 2020, WHO/HEP/HPR/2020.2, 52 (<https://www.who.int/publications/i/item/WHO-HEP-HPR-2020.2>, accessed 3 August 2020)

2 Conference of the Parties (COP) to the WHO Framework Convention on Tobacco Control (WHO FCTC), Novel and emerging tobacco products. Eight session, FCTC/COP8(22), 6 October, 2018, ([https://www.who.int/fctc/cop/sessions/cop8/FCTC\\_COP8\(22\).pdf](https://www.who.int/fctc/cop/sessions/cop8/FCTC_COP8(22).pdf), accessed 1 July 2020)

3 World Health Organization (WHO), Report on the Global Tobacco Epidemic, [2019], 56, (<https://apps.who.int/iris/bitstream/handle/10665/326043/9789241516204-eng.pdf>, accessed 3 August 2020)

4 *ibid*, 56

5 *ibid*, 56

6 Conference of the Parties (COP) to the WHO Framework Convention on Tobacco Control (WHO FCTC), Electronic nicotine delivery systems: Report by WHO, Sixth session, FCTC/COP/6/10 Rev.1, September 1, 2014, para 36 ([http://apps.who.int/gb/fctc/PDF/cop6/FCTC\\_COP6\\_10Rev1-en.pdf?ua=1](http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10Rev1-en.pdf?ua=1), accessed 15 November 2019); COP WHO FCTC, Electronic nicotine delivery systems and electronic non-nicotine delivery systems: Decision, Sixth session, FCTC/COP6(9), October 18, 2014, para 2-3 ([https://apps.who.int/gb/fctc/PDF/cop6/FCTC\\_COP6\(9\)-en.pdf](https://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6(9)-en.pdf), accessed 4 July 2020)

7 FCTC/COP/6/10 Rev.1, para 39-53

8 See COP WHO FCTC, Electronic nicotine delivery systems: Report by WHO, Seventh session, FCTC/COP/7/11. August 2016, para 28-32 ([https://www.who.int/fctc/cop/cop7/FCTC\\_COP\\_7\\_11\\_EN.pdf](https://www.who.int/fctc/cop/cop7/FCTC_COP_7_11_EN.pdf), accessed 4 August, 2020); COP WHO FCTC, Electronic nicotine delivery systems and electronic non-nicotine delivery systems: Decision, Seventh session, FCTC/COP7(9), November 12, 2016, ([https://www.who.int/fctc/cop/cop7/FCTC\\_COP7\\_9\\_EN.pdf?ua=1](https://www.who.int/fctc/cop/cop7/FCTC_COP7_9_EN.pdf?ua=1), accessed 4 August 2020)

## Box 1. Regulatory options for Member States that have not banned ENDS/ENNDS

### Prevent the initiation of ENDS/ENNDS by non-smokers and youth with special attention to vulnerable groups.

- a Banning the sale and distribution of ENDS/ENNDS to minors;
- b Banning the possession of ENDS/ENNDS by minors;
- c Banning or restricting advertising, promotion and sponsorship of ENDS/ENNDS (see FCTC/COP/6/10 Rev.1 discussed below);
- d Taxing ENDS/ENNDS at a level that makes the devices and e-liquids unaffordable to minors in order to deter its use in this age group.
- e In parallel, combustible tobacco products should be taxed at a higher level than ENDS/ENNDS to deter initiation and reduce regression to smoking;
- f Banning or restricting the use of flavours that appeal to minors;
- g Regulating places, density and channels of sales; and
- h Taking measures to combat illicit trade in ENDS/ENNDS.

### Minimize as far as possible potential health risks to ENDS/ENNDS users and protect non-users from exposure to their emissions.

- a To minimize health risks to users:
  - i. Testing heated and inhaled flavourants used in the e-liquids for safety, and banning or restricting the amount of those found to be of serious toxicological concern such as diacetyl, acetyl propionyl, cinnamaldehydes or benzaldehyde;
  - ii. Requiring the use of ingredients that are not a risk to health and are, when allowed, of the highest purity;
  - iii. Regulating electrical and fire safety standards of ENDS/ENNDS devices;
- b To minimize health risks to non-users:
  - i. Prohibiting by law the use of ENDS/ENNDS in indoor spaces or at least where smoking is not permitted;
  - ii. Requiring health warnings about potential health risks deriving from their use. Health warnings may additionally inform the public about the addictive nature of nicotine in ENDS; and
  - iii. Reducing the risk of accidental acute nicotine intoxication by (a) requiring tamper evident /

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23953](https://www.yunbaogao.cn/report/index/report?reportId=5_23953)

